$1,318.00
This Market Spotlight report covers the cervical cancer market, comprising key pipeline and marketed drugs, clinical trials, upcoming events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Cervical Cancer market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, licensing and acquisition deals, and a 10-year disease incidence forecast, as well as presenting drug-specific revenue forecasts.
Key Takeaways
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
9 TREATMENT
9 Surgery
9 Radiotherapy
9 Chemotherapy
10 Targeted therapy
10 Immunotherapy
11 EPIDEMIOLOGY
14 MARKETED DRUGS
17 PIPELINE DRUGS
24 RECENT EVENTS AND ANALYST OPINION
24 Libtayo for Cervical Cancer (January 28, 2022)
25 Balstilimab for Cervical Cancer (October 22, 2021)
25 Tivdak for Cervical Cancer (September 19, 2021)
27 Keytruda for Cervical Cancer (September 18, 2021)
29 Keytruda for Cervical Cancer (June 22, 2021)
31 Libtayo for Cervical Cancer (May 12, 2021)
32 Libtayo for Cervical Cancer (March 15, 2021)
34 Tisotumab Vedotin for Cervical Cancer (September 21, 2020)
36 Balstilimab for Cervical Cancer (September 18, 2020)
39 KEY UPCOMING EVENTS
40 KEY REGULATORY EVENTS
40 Libtayo’s Last-Minute Withdrawal
40 China’s NMPA Accepts Lee’s NDA For Socazolimab
40 Agenus PD-1 Down But Not Out With Cervical Cancer BLA Withdrawal
40 Keytruda Cements Cervical Cancer Leadership With First-Line Nod
41 Seagen/Genmab’s Tivdak Set To Take On Merck’s Keytruda
41 Agenus May Get Holiday Cheer
42 PROBABILITY OF SUCCESS
43 LICENSING AND ASSET ACQUISITION DEALS
43 GSK Exits $4.2bn Cancer Drug Deal With Merck KGaA After Multiple Failures
44 REVENUE OPPORTUNITY
46 CLINICAL TRIAL LANDSCAPE
47 Sponsors by status
48 Sponsors by phase
49 Recent events
52 BIBLIOGRAPHY
53 APPENDIX
LIST OF FIGURES
13 Figure 1: Trends in incident cases of cervical cancer, 2020–29
17 Figure 2: Overview of pipeline drugs for cervical cancer in the US
17 Figure 3: Pipeline drugs for cervical cancer, by company
18 Figure 4: Pipeline drugs for cervical cancer, by drug type
18 Figure 5: Pipeline drugs for cervical cancer, by classification
27 Figure 6: Tivdak for Cervical Cancer (September 19, 2021): Phase I/II – innovaTV 205
29 Figure 7: Keytruda for Cervical Cancer (September 18, 2021): Phase III – KEYNOTE-826 (w/Chemotherapy, 1L)
31 Figure 8: Keytruda for Cervical Cancer (June 22, 2021): Phase III – KEYNOTE-826 (w/Chemotherapy, 1L)
32 Figure 9: Libtayo for Cervical Cancer (May 12, 2021): Phase III – vs. Chemotherapy
34 Figure 10: Libtayo for Cervical Cancer (March 15, 2021): Phase III – vs. Chemotherapy
36 Figure 11: Tisotumab Vedotin for Cervical Cancer (September 21, 2020): Phase II – innovaTV 204
38 Figure 12: Balstilimab for Cervical Cancer (September 18, 2020): Phase II – RaPiDS (+/- AGEN1884, 2nd Line)
39 Figure 13: Key upcoming events in cervical cancer
42 Figure 14: Probability of success in the solid tumors pipeline
46 Figure 15: Clinical trials in cervical cancer
46 Figure 16: Top 10 drugs for clinical trials in cervical cancer
47 Figure 17: Top 10 companies for clinical trials in cervical cancer
47 Figure 18: Trial locations in cervical cancer
48 Figure 19: Cervical cancer trials status
49 Figure 20: Cervical cancer trials sponsors, by phase
LIST OF TABLES
12 Table 1: Incident cases of cervical cancer, 2020–29
15 Table 2: Marketed drugs for cervical cancer
19 Table 3: Pipeline drugs for cervical cancer in the US
24 Table 4: Libtayo for Cervical Cancer (January 28, 2022)
25 Table 5: Balstilimab for Cervical Cancer (October 22, 2021)
26 Table 6: Tivdak for Cervical Cancer (September 19, 2021)
28 Table 7: Keytruda for Cervical Cancer (September 18, 2021)
30 Table 8: Keytruda for Cervical Cancer (June 22, 2021)
31 Table 9: Libtayo for Cervical Cancer (May 12, 2021)
33 Table 10: Libtayo for Cervical Cancer (March 15, 2021)
35 Table 11: Tisotumab Vedotin for Cervical Cancer (September 21, 2020)
37 Table 12: Balstilimab for Cervical Cancer (September 18, 2020)
44 Table 13: Historical global sales, by drug ($m), 2016–20
45 Table 14: Forecasted global sales, by drug ($m), 2022–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!